The Illumina, Inc. (NASDAQ:ILMN) Downgraded by Vetr Inc.

The Illumina, Inc. (NASDAQ:ILMN) Downgraded by Vetr Inc.

ILMN has been the subject of a number of other reports. Piper Jaffray Companies reissued an “overweight” rating and issued a $187.00 price target (up from $170.00) on shares of Illumina in a research note on Friday, April 14th. Barclays PLC restated a “hold” rating and issued a $150.00 price objective on shares of Illumina in a research report on Wednesday, July 19th. TheStreet upgraded shares of Illumina from a “c+” rating to a “b” rating in a research report on Thursday, April 6th. BidaskClub cut shares of Illumina from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 25th. Finally, Cowen and Company reiterated an “outperform” rating and set a $200.00 price target on shares of Illumina in a research report on Wednesday, April 26th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company. Illumina presently has a consensus rating of “Hold” and an average target price of $174.38.

Illumina, Inc. (NASDAQ:ILMN) was downgraded by research analysts at Vetr from a “strong-buy” rating to a “hold” rating in a note issued to investors on Wednesday. They currently have a $202.18 price objective on the life sciences company’s stock. Vetr‘s target price would suggest a potential upside of 2.19% from the company’s current price.

Shares of Illumina (ILMN) traded up 14.83% on Wednesday, reaching $197.85. The company’s stock had a trading volume of 5,011,245 shares. Illumina has a 1-year low of $119.37 and a 1-year high of $198.47. The company’s 50 day moving average is $174.66 and its 200-day moving average is $171.89. The stock has a market cap of $28.89 billion, a PE ratio of 40.04 and a beta of 0.83.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.14. Illumina had a net margin of 18.13% and a return on equity of 19.50%. The business had revenue of $662 million during the quarter, compared to analyst estimates of $642.38 million. During the same period in the previous year, the business earned $0.86 EPS. Illumina’s revenue was up 10.3% compared to the same quarter last year. On average, equities analysts predict that Illumina will post $3.63 earnings per share for the current fiscal year.

In other news, Director Jay T. Flatley sold 15,000 shares of the company’s stock in a transaction on Tuesday, July 18th. The shares were sold at an average price of $170.77, for a total transaction of $2,561,550.00. Following the completion of the sale, the director now owns 534,176 shares of the company’s stock, valued at $91,221,235.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director A Blaine Bowman sold 2,300 shares of the company’s stock in a transaction on Wednesday, May 10th. The stock was sold at an average price of $181.61, for a total transaction of $417,703.00. Following the sale, the director now directly owns 18,004 shares of the company’s stock, valued at approximately $3,269,706.44. The disclosure for this sale can be found here. In the last three months, insiders sold 123,639 shares of company stock valued at $21,980,677. 1.60% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in ILMN. Vanguard Group Inc. boosted its position in Illumina by 3.0% in the first quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock worth $1,646,479,000 after buying an additional 285,379 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock valued at $896,589,000 after buying an additional 2,144,576 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Illumina by 8.0% in the first quarter. Geode Capital Management LLC now owns 1,458,071 shares of the life sciences company’s stock valued at $248,460,000 after buying an additional 107,941 shares in the last quarter. TIAA CREF Investment Management LLC boosted its stake in shares of Illumina by 40.1% in the first quarter. TIAA CREF Investment Management LLC now owns 948,121 shares of the life sciences company’s stock valued at $161,787,000 after buying an additional 271,461 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Illumina by 3.9% in the first quarter. Legal & General Group Plc now owns 651,314 shares of the life sciences company’s stock valued at $111,142,000 after buying an additional 24,613 shares in the last quarter. 93.68% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Related posts

Leave a Comment